4 documents found, page 1 of 1
Sex and body mass index impact on digit circumference for Leeds Dactylitis Inde...
Silvério-António, M; Rodrigues, AM; Teixeira, F; Tavares-Costa, J; Bernardo, A; Pimenta, S; Lagoas Gomes, J; Aguiar, R; Videira, T; Pinto, P; Santos, HObjectives: To estimate digit circumference and the impact of sex and body mass index (BMI) for the calculation of the Leeds Dactylitis Index (LDI) in psoriatic arthritis (PsA) patients with bilateral dactylitis. Methods: Digit circumference of the hands and the foot were measured with a dactylometer and were studied according to sex and BMI (divided in 4 weight categories) in healthy Portuguese subjects, using...
The GO-DACT is an investigator-initiated, national, multicentric randomized pla...
Vieira-Sousa, E; Canhão, H; Alves, P; Rodrigues, AM; Teixeira, F; Tavares-Costa, J; Bernardo, A; Pimenta, S; Pimentel-Santos, .; Gomes, JL; Aguiar, RThe GO-DACT is an investigator-initiated, national, multicentric randomized placebo-controlled double-blinded trial, that assesses dactylitis as primary endpoint. Psoriatic arthritis patients naïve to methotrexate and biologic disease modifying anti-rheumatic drugs, with at least one active dactylitis, were assigned to golimumab in combination with methotrexate or placebo in combination with methotrexate, for 2...
The GO-DACT Protocol: a Multicentre, Randomized, Double-Blind, Parallel-Group S...
Vieira-Sousa, E; Canhão, H; Alves, P; Rodrigues, AM; Teixeira, F; Tavares-Costa, J; Bernardo, A; Pimenta, S; Pimentel-Santos, F; Gomes, JL; Aguiar, RThe GO-DACT is an investigator-initiated, national, multicentric randomized placebo-controlled double-blinded trial, that assesses dactylitis as primary endpoint. Psoriatic arthritis patients naïve to methotrexate and biologic disease modifying anti-rheumatic drugs, with at least one active dactylitis, were assigned to golimumab in combination with methotrexate or placebo in combination with methotrexate, for 2...
The Portuguese Society of Rheumatology position paper on the use of biosimilars
Fonseca, JE; Gonçalves, J; Araújo, F; Cordeiro, I; Teixeira, F; Canhão, H; Pereira da Silva, JA; Garcês, S; Miranda, LC; Ramiro, Sofia; Roxo, AnaBiotechnological drugs have become a fundamental resource for the treatment of rheumatic patients. Patent expiry of some of these drugs created the opportunity for biopharmaceutical manufacturers to develop biosimilar drugs intended to be as efficacious as the originator product but with a lower cost to healthcare systems. Due to the complex manufacturing process and highly intricate structure of biologicals, a...